阿贝西利 1231929-97-7；阿贝西利游离碱 新品

产品描述

等级：活性药物成分（API）

化学名称:N - [5 - [(4-ethylpiperazin-1-yl)甲基]pyridin-2-yl] 5-fluoro-4——pyrimidin-2-amine (7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)

分子式：C27H32F2N8

分子量:506.59

规范：按照ChP/USP/EP建立企业标准

外观:粉

总杂质：不大于0.5%

纯度：不低于99%

残留溶剂：完全符合ICH Q3C要求

致突变杂质：完全符合ICH M8

亚硝胺评估：可用

粒度：可根据客户要求进行普通级或研磨/筛分。

储存方法：室温

生产能力：研发

标准包装：1kg/袋，5kg/袋，或根据客户要求

产品用途

Abemaciclib是一种人类API。它是一种抗肿瘤剂和周期蛋白依赖性激酶4 （CDK4）和6 （CDK6）的双重抑制剂，在活性不受调节的情况下参与细胞周期和促进癌细胞生长。

2017年9月28日，FDA批准abemaciclib治疗，市场名称为Verzenio，用于治疗内分泌治疗失败后进展的hr阳性和her2阴性晚期或转移性乳腺癌。在癌症转移后接受内分泌治疗和化疗的患者中，它可以单独使用，也可以与Fulvestrant联合使用。

在hr阳性、her2阴性乳腺癌患者口服治疗后，abemaciclib显示出无进展生存率和客观缓解率的增加。

Abemaciclib已被用于研究黑色素瘤、淋巴瘤、肿瘤、实体瘤和胶质母细胞瘤的治疗试验。

联系方式

四川青木制药有限公司

四川省眉山市东坡区经济开发区东区顺江大道南段55号

国际营销部(International):

Email: sales@eastonpharma.cn 

Tel: 028-87827187

国内营销部(Mainland)：

李经理 13880480517   

杨经理 15982276454

Product Description

• Grade: Active Pharmaceutical Ingredient(API)

• Chemical Name:N-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine

• Molecular Formula: C27H32F2N8

• Molecular Weight:506.59

• Specification: Enterprise Standard established according to ChP/USP/EP

• Appearance: Powder

• Total impurities: not more than 0.5%

• Purity: not less than 99%

• Residual Solvents: fully comply with ICH Q3C

• Mutagenic impurities: fully comply with ICH M8

• Nitrosamine assessment: available

• Particle size: regular grade or milling/sieving according to customer’s requirement.

• Storage: Room temperature

• Production capacity: R&D

• Standard Package: 1kg/bag, 5kg/bag, or according to the customer’s requirement

Applications 

Abemaciclib is a kind of Human API. It’s an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity.

• On September 28, 2017, the FDA granted approval for abemaciclib treatment under the market name Verzenio for the treatment of HR-positive and HER2-negative advanced or metastatic breast cancer that has progressed after unsuccessful endocrine therapy. It is either given alone in patients who have undergone endocrine therapy and chemotherapy after the metastasis of cancer, or in combination with Fulvestrant.

• Following oral treatment in patients with HR-positive, HER2-negative breast cancer, abemaciclib demonstrated increased progression-free survival rates and objective response rates.

• Abemaciclib has been used in trials studying the treatment of melanoma, lymphoma, neoplasm, solid tumor, and glioblastoma.

Contact Information

Sichuan Qingmu Pharmaceutical Co., Ltd.

Add: No. 55, South Shunjiang Avenue, East Economic Development Zone, Dongpo District, Meishan City, Sichuan, 620036, China

International Marketing Department: 

Email: sales@eastonpharma.cn 

Tel: 0086-28-87827187